A Phase 2 interventional study of Met DR and Met IR in Type 2 Diabetes Mellitus, sponsored by Elcelyx Therapeutics, Inc.. Completed at 137 sites in 2 countries. Open to participants aged 25 Years and older. Per ClinicalTrials.gov, last updated 2018-04-27.
Sponsored by Elcelyx Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 293 studies testing metformin in Diabetes Mellitus, Type 2 — 17 open to participants now, 22 under way, 2 of them phase 3. Metformin · Diabetes Mellitus, Type 2.
Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, this one is the 36th largest by enrollment of the 287 interventional ones that give a count, is one of 12 that started in 2015, is one of 23 in phase 2, and was the 204th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →17 of the 293 studies testing metformin in Diabetes Mellitus, Type 2 are open now, in 7 countries. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18–75 · Men only
JW Pharmaceutical · Sites in Korea, Republic of
Ages 19+
University of California, San Francisco · Sites in United States
Ages 10–21 · Healthy volunteers
RenJi Hospital · Sites in China
Ages 18–65
Lille Catholic University · Sites in France
Ages 18–40
By country, each count listing its studies:
Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 25 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
293 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 58 · Phase 2 31 · Phase 3 77 · Phase 4 98
First in 1996; this study’s year is marked. 12 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 571 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 100 across the 287 interventional studies. Of the 235 that completed or were terminated, 89 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
155 of 293 have an industry lead sponsor. The 10 most frequent:
Elcelyx Therapeutics, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Elcelyx Therapeutics, Inc. has 4 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
7 of the studies testing metformin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02087826Massachusetts General HospitalStudy of Clinical Response to Acute Metformin By Leveraging Evaluations During a Mixed Meal Tolerance Test for Exploring Glycemia and GeneticS | 2026-12 |
| NCT06120881University of California, San FranciscoPrecision Dosing of Metformin in Youth With T2D | 2026-12-31 |
| NCT02969798The University of Texas Health Science Center at San AntonioPre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) | 2027-02-28 |
| NCT07442006JW PharmaceuticalGlycemic Variability of Combination Therapies in T2DM | 2027-03-31 |
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to compare the glycemic effects of delayed-release metformin (Met DR) to placebo in subjects with type 2 diabetes mellitus (T2DM) over 16 weeks. The study is designed to evaluate several doses of Met DR (600 to 1500 mg once daily in the morning [qAM]) compared to placebo. A single-blind reference treatment of 2000 mg metformin immediate-release (Met IR) per day administered as equal divided doses (1000 mg Met IR BID) will also be included.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Is male, or is female and meets all of the following criteria:
Either is not treated with or has been on a stable treatment regimen with any of the following medications for a minimum of 3 months prior to Visit 1:
Exclusion Criteria:
Has a medical condition as judged by the investigator that could potentially affect study participation and/or personal well-being, including but not limited to the following conditions:
Has been treated, is currently being treated, or is expected to require or undergo treatment with any of the following excluded medications:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
600 mg metformin delayed-release once daily in the morning
Drug: Met DR
900 mg metformin delayed-release once daily in the morning
Drug: Met DR
1200 mg metformin delayed-release once daily in the morning
Drug: Met DR
1500 mg metformin delayed-release once daily in the morning
Drug: Met DR
placebo match for 600 and 1200 mg Met DR qAM treatment groups
Drug: Placebo
placebo match for 900 and 1500 mg Met DR qAM treatment groups
Drug: Placebo
1000 mg metformin immediate-release twice daily
Drug: Met IR
Change in HbA1c (%) at 16 Weeks
Time frame: Baseline and 16 weeks after the first dose of study medication
| Milestone | 600 mg Met DR qAM | 900 mg Met DR qAM | 1200 mg Met DR qAM | 1500 mg Met DR qAM | Placebo | 2000 mg Met IR |
|---|---|---|---|---|---|---|
| Started | 94 | 95 | 96 | 96 | 96 | 94 |
| Completed | 82 | 86 | 70 | 89 | 72 | 73 |
| Not completed | 12 | 9 | 26 | 7 | 24 | 21 |
| Withdrew: Withdrawal by subject | 3 | 3 | 6 | 1 | 9 | 5 |
| Withdrew: Adverse event | 3 | 2 | 4 | 2 | 6 | 8 |
| Withdrew: Lost to follow-up | 2 | 3 | 8 | 1 | 2 | 5 |
| Withdrew: Protocol violation | 3 | 1 | 5 | 3 | 4 | 3 |
| Withdrew: Loss of glucose control | 0 | 0 | 3 | 0 | 2 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Sponsor decision | 1 | 0 | 0 | 0 | 0 | 0 |
| % glycated haemoglobin | 600 mg Met DR qAM | 900 mg Met DR qAM | 1200 mg Met DR qAM | 1500 mg Met DR qAM | Placebo | 2000 mg Met IR |
|---|---|---|---|---|---|---|
| Change in HbA1c (%) at 16 Weeks | -0.33 ± 0.129 | -0.40 ± 0.123 | -0.49 ± 0.129 | -0.62 ± 0.124 | -0.06 ± 0.131 | -1.10 ± 0.129 |
Collected over 16 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 600 mg Met DR qAM | 0/94 (0%) | 1/94 (1.1%) | 19/94 (20.2%) |
| 900 mg Met DR qAM | 0/95 (0%) | 0/95 (0%) | 24/95 (25.3%) |
| 1200 mg Met DR qAM | 0/96 (0%) | 4/96 (4.2%) | 19/96 (19.8%) |
| 1500 mg Met DR qAM | 0/96 (0%) | 1/96 (1%) | 20/96 (20.8%) |
| Placebo | 1/96 (1%) | 4/96 (4.2%) | 17/96 (17.7%) |
| 2000 mg Met IR | 0/94 (0%) | 1/94 (1.1%) | 23/94 (24.5%) |
| Event | 600 mg Met DR qAM | 900 mg Met DR qAM | 1200 mg Met DR qAM | 1500 mg Met DR qAM | Placebo | 2000 mg Met IR |
|---|---|---|---|---|---|---|
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/94 | 0/95 | 0/96 | 0/96 | 0/96 | 1/94 |
| HidradenitisSkin and subcutaneous tissue disorders | 1/94 | 0/95 | 0/96 | 0/96 | 0/96 | 0/94 |
| Colitis ischaemicGastrointestinal disorders | 0/94 | 0/95 | 0/96 | 0/96 | 1/96 | 0/94 |
| DeathGeneral disorders | 0/94 | 0/95 | 0/96 | 0/96 | 1/96 | 0/94 |
| Arthritis bacterialInfections and infestations | 0/94 | 0/95 | 1/96 | 0/96 | 0/96 | 0/94 |
| OsteomyelitisInfections and infestations | 0/94 | 0/95 | 0/96 | 0/96 | 1/96 | 0/94 |
| Pelvic inflammatory diseaseInfections and infestations | 0/94 | 0/95 | 0/96 | 0/96 | 1/96 | 0/94 |
| ObesityMetabolism and nutrition disorders | 0/94 | 0/95 | 1/96 | 0/96 | 0/96 | 0/94 |
| ArthritisMusculoskeletal and connective tissue disorders | 0/94 | 0/95 | 0/96 | 1/96 | 0/96 | 0/94 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/94 | 0/95 | 1/96 | 0/96 | 0/96 | 0/94 |
| Event | 600 mg Met DR qAM | 900 mg Met DR qAM | 1200 mg Met DR qAM | 1500 mg Met DR qAM | Placebo | 2000 mg Met IR |
|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 7/94 | 7/95 | 11/96 | 11/96 | 0/96 | 13/94 |
| HyperglycemiaMetabolism and nutrition disorders | 8/94 | 10/95 | 7/96 | 8/96 | 10/96 | 5/94 |
| NauseaGastrointestinal disorders | 3/94 | 3/95 | 1/96 | 3/96 | 1/96 | 9/94 |
| Upper respiratory tract infectionInfections and infestations | 1/94 | 5/95 | 1/96 | 0/96 | 2/96 | 2/94 |
| Worsening Type 2 diabetes mellitusMetabolism and nutrition disorders | 3/94 | 1/95 | 0/96 | 0/96 | 5/96 | 0/94 |
Intent-to-Treat Population: Subjects who took at least one dose of randomized study medication.
| Age, Continuous(years) | 600 mg Met DR qAM | 900 mg Met DR qAM | 1200 mg Met DR qAM | 1500 mg Met DR qAM | Placebo | 2000 mg Met IR | Total |
|---|---|---|---|---|---|---|---|
| Mean | 56 ± 10.2 | 55 ± 10.5 | 55 ± 11.1 | 55 ± 8.9 | 57 ± 11.0 | 57 ± 11.1 | 56 ± 10.5 |
| Sex: Female, Male(Participants) | 600 mg Met DR qAM | 900 mg Met DR qAM | 1200 mg Met DR qAM | 1500 mg Met DR qAM | Placebo | 2000 mg Met IR | Total |
|---|---|---|---|---|---|---|---|
| Female | 46 | 38 | 45 | 42 | 53 | 45 | 269 |
| Male | 48 | 57 | 51 | 54 | 43 | 49 | 302 |
| Ethnicity (NIH/OMB)(Participants) | 600 mg Met DR qAM | 900 mg Met DR qAM | 1200 mg Met DR qAM | 1500 mg Met DR qAM | Placebo | 2000 mg Met IR | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 36 | 44 | 41 | 42 | 37 | 45 | 245 |
| Not Hispanic or Latino | 58 | 51 | 55 | 54 | 59 | 49 | 326 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 600 mg Met DR qAM | 900 mg Met DR qAM | 1200 mg Met DR qAM | 1500 mg Met DR qAM | Placebo | 2000 mg Met IR | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 0 | 0 | 1 | 2 |
| Asian | 3 | 6 | 3 | 3 | 5 | 2 | 22 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 1 | 1 | 0 | 2 |
| Black or African American | 14 | 7 | 23 | 19 | 17 | 8 | 88 |
| White | 75 | 82 | 70 | 73 | 72 | 82 | 454 |
| More than one race | 1 | 0 | 0 | 0 | 0 | 1 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Body Weight(kg) | 600 mg Met DR qAM | 900 mg Met DR qAM | 1200 mg Met DR qAM | 1500 mg Met DR qAM | Placebo | 2000 mg Met IR | Total |
|---|---|---|---|---|---|---|---|
| Mean | 94 ± 19.9 | 89 ± 18.5 | 93 ± 20.9 | 95 ± 22.2 | 86 ± 17.1 | 89 ± 21.3 | 91 ± 20.2 |
| Body Mass Index(kg/m²) | 600 mg Met DR qAM | 900 mg Met DR qAM | 1200 mg Met DR qAM | 1500 mg Met DR qAM | Placebo | 2000 mg Met IR | Total |
|---|---|---|---|---|---|---|---|
| Mean | 33 ± 5.1 | 32 ± 5.5 | 32 ± 5.9 | 33 ± 5.8 | 31 ± 5.1 | 32 ± 5.4 | 32 ± 5.5 |
| HbA1c(%) | 600 mg Met DR qAM | 900 mg Met DR qAM | 1200 mg Met DR qAM | 1500 mg Met DR qAM | Placebo | 2000 mg Met IR | Total |
|---|---|---|---|---|---|---|---|
| Mean | 8.6 ± 0.85 | 8.7 ± 0.82 | 8.7 ± 0.90 | 8.6 ± 0.94 | 8.6 ± 0.87 | 8.6 ± 0.92 | 8.6 ± 0.88 |
| HbA1c stratum(Participants) | 600 mg Met DR qAM | 900 mg Met DR qAM | 1200 mg Met DR qAM | 1500 mg Met DR qAM | Placebo | 2000 mg Met IR | Total |
|---|---|---|---|---|---|---|---|
| <8.5% | 45 | 45 | 46 | 46 | 45 | 45 | 272 |
| ≥8.5% | 49 | 50 | 50 | 50 | 51 | 49 | 299 |
5 further baseline measures are reported on the registry.
Showing the first 100 of 137 sites across 2 countries. Choose a country and city above to see the rest.
The record gives a start of Sep 2015, a primary completion of Sep 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2018, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metformin
Elcelyx Therapeutics, Inc.